HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation

REFERENCES

• Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005;34(Suppl 1):S1–S3.
   PubMed Web of Science ®Google Scholar
• WHO. Hepatitis B fact sheet [cited 2013 March]. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/index.html.
   Google Scholar
• Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335–352.
   PubMed Web of Science ®Google Scholar
• Samuel D. The option of liver transplantation for hepatitis B: where are we? Dig Liver Dis 2009;41(Suppl 2):S185–S189.
   PubMedGoogle Scholar
• Seaberg EC, Belle SH, Beringer KC, Liver transplantation in the United States from 1987–1998: updated results from the Pitt-UNOS Liver Transplant Registry. Clin Transpl 1998:17–37.
   PubMedGoogle Scholar
• Lo CM, Fan ST, Liu CL, Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Transplantation 2003;75:S41–S44.
   PubMed Web of Science ®Google Scholar
• Davies SE, Portmann BC, O’Grady JG, Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991;13:150–157.
   PubMed Web of Science ®Google Scholar
• Todo S, Demetris AJ, Van Thiel D, Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991;13:619–626.
   PubMed Web of Science ®Google Scholar
• O’Grady JG, Smith HM, Davies SE, Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992;14:104–111.
   PubMed Web of Science ®Google Scholar
• Belle SH, Beringer KC, Murphy JB, Detre KM. The Pitt-UNOS Liver Transplant Registry. Clin Transpl 1992:17–32.
   PubMedGoogle Scholar
• Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012;142:1373–1383 e1.
   PubMed Web of Science ®Google Scholar
• Freeman RB, Sanchez H, Lewis WD, Serologic and DNA follow-up data from HBsAg-positive patients treated with orthotopic liver transplantation. Transplantation 1991;51:793–797.
   PubMed Web of Science ®Google Scholar
• Rizzetto M, Recchia S, Salizzoni M. Liver transplantation in carriers of the HBsAg. J Hepatol 1991;13:5–7.
   PubMed Web of Science ®Google Scholar
• Konig V, Hopf U, Neuhaus P, Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994;58:553–559.
   PubMed Web of Science ®Google Scholar
• Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000;32:1189–1195.
   PubMed Web of Science ®Google Scholar
• Rosenau J, Bahr MJ, Tillmann HL, Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001;34:895–902.
   PubMed Web of Science ®Google Scholar
• Honaker MR, Shokouh-Amiri MH, Vera SR, Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Transpl Infect Dis 2002;4:137–143.
   PubMedGoogle Scholar
• Van Thiel DH, Schade RR, Gavaler JS, Medical aspects of liver transplantation. Hepatology 1984;4:79S-83S.
   PubMed Web of Science ®Google Scholar
• Cai CJ, Lu MQ, Chen YH, Clinical study on prevention of HBV re-infection by entecavir after liver transplantation. Clin Transplant 2012;26:208–215.
   PubMed Web of Science ®Google Scholar
• Yi NJ, Suh KS, Cho JY, Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2007;13:451–458.
   PubMed Web of Science ®Google Scholar
• Sawyer RG, McGory RW, Gaffey MJ, Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998;227:841–850.
   PubMed Web of Science ®Google Scholar
• Schilling R, Ijaz S, Davidoff M, Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol 2003;77:8882–8892.
   PubMed Web of Science ®Google Scholar
• Samuel D, Muller R, Alexander G, Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842–1847.
   PubMed Web of Science ®Google Scholar
• Samuel D, Bismuth A, Mathieu D, Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991;337:813–815.
   PubMed Web of Science ®Google Scholar
• McGory RW, Ishitani MB, Oliveira WM, Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61:1358–1364.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Zhou S, Combs C, Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996;24:1327–1333.
   PubMed Web of Science ®Google Scholar
• Devlin J, Smith HM, O’Grady JG, Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients. J Hepatol 1994;21:204–210.
   PubMed Web of Science ®Google Scholar
• Lauchart W, Muller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 1987;19:4051–4053.
   PubMed Web of Science ®Google Scholar
• Muller R, Gubernatis G, Farle M, Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991;13:90–96.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Zhou S, McCory RW, Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998;28:555–561.
   PubMed Web of Science ®Google Scholar
• Laryea MA, Watt KD. Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation. Liver Transpl 2012;18:514–523.
   PubMed Web of Science ®Google Scholar
• Lowell JA, Burgess S, Shenoy S, Mercury poisoning associated with hepatitis-B immunoglobulin. Lancet 1996;347:480.
   PubMed Web of Science ®Google Scholar
• al-Hemsi B, McGory RW, Shepard B, Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization. Clin Transplant 1996;10:668–675.
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Wright T, Rakela J, A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424–432.
   PubMed Web of Science ®Google Scholar
• Roche B, Feray C, Gigou M, HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003;38:86–95.
   PubMed Web of Science ®Google Scholar
• Bartholomew MM, Jansen RW, Jeffers LJ, Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20–22.
   PubMed Web of Science ®Google Scholar
• Cariani E, Ravaggi A, Tanzi E, Emergence of hepatitis B virus S gene mutant in a liver transplant recipient. J Med Virol 1995;47:410–415.
   PubMed Web of Science ®Google Scholar
• Carman WF, Trautwein C, van Deursen FJ, Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996;24:489–493.
   PubMed Web of Science ®Google Scholar
• Hawkins AE, Gilson RJ, Gilbert N, Hepatitis B virus surface mutations associated with infection after liver transplantation. J Hepatol 1996;24:8–14.
   PubMed Web of Science ®Google Scholar
• Ling R, Mutimer D, Ahmed M, Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711–713.
   PubMed Web of Science ®Google Scholar
• McMahon G, Ehrlich PH, Moustafa ZA, Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 1992;15:757–766.
   PubMed Web of Science ®Google Scholar
• Ghany MG, Ayola B, Villamil FG, Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998;27:213–222.
   PubMed Web of Science ®Google Scholar
• Dindoost P, Jazayeri SM, Alavian SM. Hepatitis B immune globulin in liver transplantation prophylaxis: an update. Hepat Monthly 2012;12:168–176.
   PubMed Web of Science ®Google Scholar
• Avolio AW, Nure E, Pompili M, Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches. Transplant Proc 2008;40:1961–1964.
   PubMed Web of Science ®Google Scholar
• Hwang S, Lee SG, Ahn CS, Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transpl 2008;14:770–778.
   PubMed Web of Science ®Google Scholar
• Roche B, Roque-Afonso AM, Sebagh M, Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins. Liver Transpl 2010;16:885–894.
   PubMed Web of Science ®Google Scholar
• Hooman N, Rifai K, Hadem J, Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 2008;14:435–442.
   PubMed Web of Science ®Google Scholar
• Filipponi F, Franchello A, Carrai P, Efficacy, safety, and pharmacokinetics of intramuscular hepatitis B immune globulin, Igantibe, for the prophylaxis of viral B hepatitis after liver transplantation. Dig Liver Dis 2010;42:509–514.
   PubMedGoogle Scholar
• Targhetta S, Villamil F, Inturri P, Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease. World J Gastroenterol 2006;12:1706–1712.
   PubMed Web of Science ®Google Scholar
• Umeda M, Marusawa H, Ueda M, Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation. Am J Transplant 2006;6:2680–2685.
   PubMed Web of Science ®Google Scholar
• Kruger M. European hepatitis B immunoglobulin trials: prevention of recurrent hepatitis B after liver transplantation. Clin Transplant 2000;14(Suppl 2):14–19.
   PubMed Web of Science ®Google Scholar
• Faust D, Rabenau HF, Allwinn R, Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant 2003;17:254–258.
   PubMed Web of Science ®Google Scholar
• Franciosi M, Caccamo L, De Simone P, Development and validation of a questionnaire evaluating the impact of hepatitis B immune globulin prophylaxis on the quality of life of liver transplant recipients. Liver Transpl 2012;18:332–339.
   PubMed Web of Science ®Google Scholar
• Singham J, Greanya ED, Lau K, Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence. Ann Hepatol 2010;9:166–171.
   PubMed Web of Science ®Google Scholar
• Levstik M, Wong P, Greanya ED, Yoshida EM. The role of hepatitis B immunoglobulin in hepatitis B related liver transplantation: Canadian Transplant Centre Position Paper. Ann Hepatol 2011;10:441–444.
   PubMed Web of Science ®Google Scholar
• Klein CG, Cicinnati V, Schmidt H, Compliance and tolerability of subcutaneous hepatitis B immunoglobulin self-administration in liver transplant patients: A prospective, observational, multicenter study. Ann Transplant 2013;18:677–684.
   PubMed Web of Science ®Google Scholar
• Powell JJ, Apiratpracha W, Partovi N, Subcutaneous administration of hepatitis B immune globulin in combination with lamivudine following orthotopic liver transplantation: effective prophylaxis against recurrence. Clin Transplant 2006;20:524–525.
   PubMed Web of Science ®Google Scholar
• Yahyazadeh A, Beckebaum S, Cicinnati V, Efficacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra) in liver transplantation: an open, prospective, single-arm phase III study. Transpl Int 2011;24:441–450.
   PubMed Web of Science ®Google Scholar
• Dickson RC, Terrault NA, Ishitani M, Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl 2006;12:124–133.
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Perrillo RP, Schiff ER, A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657–1661.
   PubMed Web of Science ®Google Scholar
• Schreibman IR, Schiff ER. Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann Clin Microbiol Antimicrob 2006;5:8.
   PubMedGoogle Scholar
• Malkan G, Cattral MS, Humar A, Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation 2000;69:1403–1407.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Kato T, Levi DM, Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clin Transplant 2007;21:166–171.
   PubMed Web of Science ®Google Scholar
• Lo CM, Cheung ST, Lai CL, Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001;233:276–281.
   PubMed Web of Science ®Google Scholar
• Lu Y, Wang B, Yu L, Lamivudine in prevention and treatment of recurrent HBV after liver transplantation. Hepatobiliary Pancreat Dis Int 2004;3:504–507.
   PubMedGoogle Scholar
• Grellier L, Mutimer D, Ahmed M, Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212–1215.
   PubMed Web of Science ®Google Scholar
• Mutimer D, Dusheiko G, Barrett C, Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000;70:809–815.
   PubMed Web of Science ®Google Scholar
• Seta T, Yokosuka O, Imazeki F, Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. J Med Virol 2000;60:8–16.
   PubMed Web of Science ®Google Scholar
• Limquiaco JL, Wong J, Wong VW, Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. J Med Virol 2009;81:224–229.
   PubMed Web of Science ®Google Scholar
• Schiff E, Lai CL, Hadziyannis S, Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007;13:349–360.
   PubMed Web of Science ®Google Scholar
• Saab S, Ham MY, Stone MA, Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transpl 2009;15:413–420.
   PubMed Web of Science ®Google Scholar
• Stravitz RT, Shiffman ML, Kimmel M, Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver Int 2012;32:1138–1145.
   PubMed Web of Science ®Google Scholar
• Wesdorp DJ, Knoester M, Braat AE, Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. J Clin Virol 2013;58:67–73.
   PubMed Web of Science ®Google Scholar
• Perrillo R, Buti M, Durand F, Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl 2013;19:887–895.
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Vasiliadis T, Antoniadis N, Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis 2012;14:479–487.
   PubMed Web of Science ®Google Scholar
• Saab S, Desai S, Tsaoi D, Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant 2011;11:511–517.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M, Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442–2455.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:91–100.
   PubMed Web of Science ®Google Scholar
• Fung J, Chan SC, Cheung C, Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol 2013;108:942–948.
   PubMed Web of Science ®Google Scholar
• Fung J, Cheung C, Chan SC, Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011;141:1212–1219.
   PubMed Web of Science ®Google Scholar
• Villamil FG. Prophylaxis with anti-HBs immune globulins and nucleoside analogues after liver transplantation for HBV infection. J Hepatol 2003;39:466–474.
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Martin P, Conrad AJ, Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998;28:585–589.
   PubMed Web of Science ®Google Scholar
• Buti M, Mas A, Prieto M, A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003;38:811–817.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Angus PW, Strasser S, Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007;132:931–937.
   PubMed Web of Science ®Google Scholar
• Bzowej N, Han S, Degertekin B, Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl 2009;15:1010–1020.
   PubMed Web of Science ®Google Scholar
• Kim WR, Poterucha JJ, Kremers WK, Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004;10:968–974.
   PubMed Web of Science ®Google Scholar
• Yataco M, Bonatti H, Machicao V, Long term survival and complications after liver transplantation in patients with chronic hepatitis B. Ann Transplant 2010;15:27–34.
   PubMed Web of Science ®Google Scholar
• Marzano A, Salizzoni M, Debernardi-Venon W, Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903–910.
   PubMed Web of Science ®Google Scholar
• Han SH, Ofman J, Holt C, An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000;6:741–748.
   PubMed Web of Science ®Google Scholar
• Steinmuller T, Seehofer D, Rayes N, Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002;35:1528–1535.
   PubMed Web of Science ®Google Scholar
• Rosenau J, Tillmann HL, Bahr MJ, Successful hepatitis B reinfection prophylaxis with lamivudine and hepatitis B immune globulin in patients with positive HBV-DNA at time of liver transplantation. Transplant Proc 2001;33:3637–3638.
   PubMed Web of Science ®Google Scholar
• Loomba R, Rowley AK, Wesley R, Hepatitis B immunoglobulin and lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008;6:696–700.
   PubMed Web of Science ®Google Scholar
• Katz LH, Paul M, Guy DG, Tur-Kaspa R. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect Dis 2010;12:292–308.
   PubMed Web of Science ®Google Scholar
• Chen J, Yi L, Jia JD, Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation: a systematic review. J Gastroenterol Hepatol 2010;25:872–879.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhang Q, Cai CJ, Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant. Chin Med J (Engl) 2007;120:1400–1403.
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011;17:1176–1190.
   PubMed Web of Science ®Google Scholar
• Ueda Y, Marusawa H, Kaido T, Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation. Hepatol Res: the official journal of the Japan Society of Hepatology 2013;43:67–71.
   PubMed Web of Science ®Google Scholar
• Campos-Varela I, Castells L, Buti M, Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues? Ann Hepatol 2011;10:180–187.
   PubMed Web of Science ®Google Scholar
• Yilmaz N, Shiffman ML, Todd Stravitz R, Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. Liver Int 2008;28:72–78.
   PubMed Web of Science ®Google Scholar
• Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009;15:2489–2499.
   PubMed Web of Science ®Google Scholar
• Marzano A. The prevention of viral recurrence in the long term. Dig Liver Dis 2009;41(Suppl 2):S195–S197.
   PubMedGoogle Scholar
• Yan ML, Yan LN, Li B, Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2006;5:360–363.
   PubMedGoogle Scholar
• Zheng S, Chen Y, Liang T, Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006;12:253–258.
   PubMed Web of Science ®Google Scholar
• Anderson RD, Chinnakotla S, Guo L, Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens. Clin Transplant 2007;21:510–517.
   PubMed Web of Science ®Google Scholar
• Woo HY, Choi JY, Jang JW, Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. J Med Virol 2008;80:1891–1899.
   PubMed Web of Science ®Google Scholar
• Giusto MGF, Loria I, Grieco S, Combined therapy with low dose hepatitis B immunoglobulin (HBIG) and lamivudine (LAM) in patients transplanted for HBV chronic liver disease: long term efficacy and costs [abstract]. J hepatol 2008;48(Suppl 2):S84.
   Web of Science ®Google Scholar
• Jiang L, Yan L, Li B, Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant 2010;10:1861–1869.
   PubMed Web of Science ®Google Scholar
• Angus PW, McCaughan GW, Gane EJ, Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000;6:429–433.
   PubMed Web of Science ®Google Scholar
• Han SH, Martin P, Edelstein M, Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003;9:182–187.
   PubMed Web of Science ®Google Scholar
• Di Costanzo GG, Lanza AG, Picciotto FP, Safety and efficacy of subcutaneous hepatitis B immunoglobulin after liver transplantation: an open single-arm prospective study. Am J Transplant 2013;13:348–352.
   PubMed Web of Science ®Google Scholar
• Naoumov NV, Lopes AR, Burra P, Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001;34:888–894.
   PubMed Web of Science ®Google Scholar
• Buti M, Mas A, Prieto M, Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007;84:650–654.
   PubMed Web of Science ®Google Scholar
• Angus PW, Patterson SJ, Strasser SI, A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008;48:1460–1466.
   PubMed Web of Science ®Google Scholar
• Lo CM, Liu CL, Lau GK, Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005;11:807–813.
   PubMed Web of Science ®Google Scholar
• Neff GW, Kemmer N, Kaiser TE, Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci 2007;52:2497–2500.
   PubMed Web of Science ®Google Scholar
• Sevmis S, Aktas S, Zia HH, Long-term results of hepatitis B immunoglobulin and lamuvidine for hepatitis B prophylaxis after liver transplantation. Transplant Proc 2011;43:598–600.
   PubMed Web of Science ®Google Scholar
• Teperman LW, Poordad F, Bzowej N, Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl 2013;19(6):594–601.
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant 2013;13:353–362.
   PubMed Web of Science ®Google Scholar
• Lenci I, Tisone G, Di Paolo D, Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol 2011;55:587–593.
   PubMed Web of Science ®Google Scholar